Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prulifloxacin - Nippon Shinyaku

Next Previous
X
Search
Drug Profile

Prulifloxacin - Nippon Shinyaku

Alternative Names: AF 3012; NAD-441A; NM441; OPT-99; PrulifloxacinA brs; Pruvel; Quisnon; Sword; Sword 100; Unidrox

Latest Information Update: 14 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nippon Shinyaku
  • Developer Angelini Group; Cubist Pharmaceuticals; Lee's Pharmaceutical; Merck & Co; Nippon Shinyaku; Optimer Pharmaceuticals
  • Class Antibacterials; Dioxolanes; Fluoroquinolones; Piperazines; Quinolones; Small molecules
  • Mechanism of Action Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute exacerbations of chronic bronchitis; Bacterial infections; Gram-negative infections; Gram-positive infections; Pneumonia; Respiratory tract infections; Urinary tract infections
  • Phase III Prostatitis; Traveller's diarrhoea

Most Recent Events

  • 14 Nov 2018 Launched for Acute exacerbations of chronic bronchitis in China (PO) prior to November 2018 (Lees Pharmaceutical Holdings website, November 2018)
  • 01 Jul 2015 Lees Pharmaceutical completes a phase III trial in Urinary tract infections in China (NCT02439632)
  • 13 May 2015 Prulifloxacin is still in phase-III development for Prostatitis, Traveller's diarrhoea and Acute exacerbations of chronic bronchitis in Italy

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top